NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe
- Combines NewAmsterdam's lead clinical program obicetrapib with Menarini's deep cardiovascular disease and regional expertise - Total deal value of over €1 billion; including €142.5 million upfront payment and committed R&D funding plus potential milestones and double-digit royalties on net product sales in Europe - Obicetrapib is a next-generation oral, low-dose and...
Kensing Announces Acquisition of Vitae Naturals
Transaction Creates a Global Leader in Plant Sterol Esters and Natural Vitamin E KANKAKEE, Ill., June 28, 2022 /PRNewswire/ -- Kensing, LLC ("Kensing" or the "Company"), a leading manufacturer of Natural Vitamin E, Plant Sterols and high-purity surfactants, and a portfolio company of One Rock Capital Partners, LLC ("One Rock"), today announced its acquisition of Vitae Naturals ("Vitae"), a...
OME Health, a UK-based DIGITAL health company, announces the launch of a novel health and nutrition coaching platform on the heels of a new funding round
LONDON, June 28, 2022 /PRNewswire/ -- OME Health recently closed a new funding round led by Gen-tech Investments, with the participation of global pharmaceutical company Bayer AG, leading athletics company ASICS Ltd., and existing investors. The company also launched a B2B nutrition and health coaching platform to help health professionals manage and scale their practices. OME Health has used...
Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies
Palleon and Henlius to co-develop Bifunctional HER2-Sialidase and a second bifunctional sialidase to be jointly designed - Henlius received exclusive license for two products in China (including Hong Kong, Macau, and Taiwan); Palleon retains all other global rights - Palleon receives upfront payment and is eligible for up to $196.5 million in milestone payments - SHANGHAI, June...
iNtRON to Seek a New Clinical Partner for SAL200 Endolysin
TONABACASE, the first registered INN by WHO for Endolysin First-in-Class Endolysin-based Drug against Superbugs US FDA Phase 2 IND Approval for TONABACASE, SAL200 Roivant has returned the rights for the asset just before the first patient injection BOSTON and SEOUL, South Korea, June 28, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON") announced today that SAL200, a endolysin-based novel...
New hope for IVF patients as global study published in Human Reproduction shows AI can effectively assess genetic integrity of embryos
SAN FRANCISCO, June 28, 2022 /PRNewswire/ -- Human Reproduction journal has published the ground-breaking results of an international clinical study, where a novel AI algorithm called Life Whisperer Genetics was developed by AI healthcare company Presegen to assess the genetic integrity of embryos using only images. The assessment is non-invasive, low-cost, and...
Seegene develops PCR test to detect monkeypox virus
Assay targets monkeypox virus and can deliver results in 90 minutes Company swiftly rolls out product using its automated assay development system "Seegene will strive to make accurate tests for emerging viruses to help prevent future pandemics" SEOUL, South Korea, June 28, 2022 /PRNewswire/ -- Seegene Inc. (KQ965390), South...
Ascletis Announced First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection
-- The Phase II clinical study in China is currently expected to be completed in early 2023 with an expected enrollment of 30 subjects HANGZHOU, China and SHAOXING, China, June 28, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the first subject has been dosed in the China Phase II clinical trial of...
Clarivate Names World’s Leading Journals with the 2022 Journal Citation Reports
Continued increase in citation impact for journals publishing COVID-19 research LONDON, June 28, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today released the 2022 update to its annual Journal Citation Reports (JCR)™. The annual JCR release enables...
Sinohealth Holdings Limited Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange
Offer Price Between HK$5.36 and HK$6.96 per Share To Raise Proceeds Up to HK$522 million The Largest Provider of Healthcare Insight Solutions for Medical Products and Channels in China HONG KONG, June 28, 2022 /PRNewswire/ -- A leading healthcare insight solutions provider in China - Sinohealth Holdings Limited ("Sinohealth Holdings" or the "Company", stock code: 2361.HK, together...
